It seems that despite potential role of reactive oxygen species (ROS) in evolving resistant mutations in BCR-ABL fusion gene, oxidative stress exerts beneficial roles in boosting the efficiency of CML drug therapies. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.